(More on government funded inventions here)
2015
- 2015: Virotas Biopharmaceuticals. KEI and Public Citizen ask NIH for safeguards in license for HCV patents, April 14, 2015.
- 2015: NIH refuses to give information about principals in company seeking exclusive license to HCV patents, May 5, 2015.
2016
- 2016: KEI comments on NIH proposal for exclusive licenses for vitro diagnostics patents to AltraTech, February 23, 2016.
- 2016: KEI/MSF comments to NIH on licensing of patents on Attenuated Respiratory Syncytial Virus (RSV) Vaccines, March 9, 2016.
- 2016: Objection to exclusive license to AestasRx Inc, April 8, 2016.
- 2016: Midissia Therapeutics license of NIH owned breast and prostate cancer vaccine patents, April 8, 2016.
- 2016: Great Lakes Neuroscience and NIH exclusive license on MS/ALS patent, April 10, 2016.
- 2016: NIH license on patents on 5T4 Antibodies for cancer treatment, diagnostics, to Ovensa, located in Ontario, Canada, April 17, 2016.
- 2016: NIH licenses on Boron Neutron patents, to Beijing Lanyears Communication, April 19, 2016.
- 2016: KEI objections to NIH licenses to Vital Spark, Kalytera Therapeutics, CB1 receptor mediating compounds, May 4, 2016.
- 2016: NIH FOIA office withholds all records related to exclusive license on HER2+ breast cancer treatment technology, May 4, 2016.
- 2016: KEI comments on NIH proposal for exclusive licenses to Dedalus Pharma, LLC, May 9, 2016.
- 2016: AAVMediated Aquaporin Gene Transfer To Treat Sjögren’s Syndrome, May 16, 2016.
- 2016: KEI comments on NIH proposal for exclusive licenses to Lentigen Technology, Inc., June 2, 2016.
- 2016: KEI comments on NIH proposal for exclusive licenses to Chimeron Bio Corporation, June 2, 2016.
- 2016: KEI comments on NIH proposal for exclusive licenses to Etubics Corporation, June 3, 2016.
- 2016: KEI comments on NIH proposal for exclusive licenses to IntelliPanel Medical, LLC, June 3, 2016.
- 2016: KEI comments on NIH proposal for exclusive licenses to Dimension Therapeutics, Inc., June 8, 2016.
- 2016: NIH Waivers for U.S. Manufacturing Requirements for Federally-Funded Drugs, September 17, 2016.
- 2016: Kite Pharma Press Releases & News Stories Related to Relationship with National Cancer Institute, October 19, 2016.
- 2016: Kite Pharma Uses CRADAs to Conduct Important Clinical Research on New Cancer Treatments, October 19, 2016.
- 2016: KEI comments on NIH proposed Exclusive License to Kite Pharma for Cancer Treatment, October 20, 2016.
- 2016: Front page New York Times story explores Kite Pharma’s profitable relationship with NIH regarding expensive cancer drug, Dec 20, 2016.
2017
- 2017: GeneXion Oncology Prospective Grant of Exclusive Patent License for Mutant IDH1 Inhibitors Useful for Treating Cancer, May 31, 2017.
- 2017: AbPro license of patents for liver cancer, June 2, 2017.
- 2017: PathoVax license on Chimeric L1/L2 Protein and Virus-Like Particles Based Human Papillomavirus Vaccines, June 5, 2017.
- 2017: NantBioScience – Commercial Application and Use of Fulvestrant in Combination Therapy for the Treatment of Cancers, July 22, 2017.
- 2017: VeriLuce license of patents for pancreatic cancer treatment, July 31, 2017.
- 2017: Salubris Biotherapeutics: Bispecific, Biparatopic Antibody-Drug Conjugate for Human Liver Cancers, August 8, 2017.
- 2017: KEI initial comments on NIH proposed grant of exclusive license on liver cancer treatment to Salubris, August 8, 2017.
- 2017: miRecule/NIH license on MicroRNA Therapeutics for Treating Squamous Cell Carcinomas, August 18, 2017.
- 2017: Nanobernetics proposed exclusive license for NIH patents on Apparatus for Microarray Binding Sensors, September 6, 2017.
- 2017: National Institutes of Health proposed exclusive license for kidney cancer patents to company without its own phone number, Dec 21, 2017.
- 2017: KEI and MSF release comments on the proposed license of Zika vaccine candidates to PaxVax, November 13, 2017.
- 2017: NIH non-response response to KEI and MSF comments on the proposed exclusive license of Zika vaccine patents to PaxVax, Nov 30, 2017.
2018
- 2018: Briefing note on NIH proposed license to Gilead for CD-30 CAR T technology, January 5, 2018.
- 2018: KEI Appeals NIH/NCI Decision to Proceed with License of CD30 CAR T technology to Gilead/Kite. February 27, 2018.
- 2018: KEI sues NIH over license of CD30 CAR T patents to Gilead, April 19, 2018.
- 2018: KEI, HealthGap comments on NIH exclusive license to Precision IBD for patents on TLIA Antibodies, May 23, 2018.
- 2018: Comments on Morphiex Biotherapeutics license (and NIH Response), May 30, 2018.
- 2018: NIH files motion to dismiss in KEI/NIH/Gilead CAR T license lawsuit, June 8, 2018.
- 2018: Comments on a prospective exclusive license of NIH-owned inventions to Beoro Therapeutics, June 22, 2018.
- 2018: KEI Files Expedited FOIA Request Regarding NIH Prospective Exclusive License of CAR T Technology, June 29, 2018.
- 2018: KEI comments on prospective exclusive NIH license to streptococcus pneumonia patents, for the University of Liverpool, July 3, 2018.
- 2018: NIH asked to extend comments on proposed license to Atara Biotherapeutics for patents on CAR T, July 9, 2018.
- 2018: KEI comments: ERYTHRYx Therapeutics: Prospective Grant of an Exclusive License on Methods of Modulating Erythropoiesis, July 9, 2018.
- 2018: KEI comments on the prospective grant of an exclusive license: Mutant IDH1 inhibitors for treating cancer to Apexx Oncology (and NIH Response), July 10, 2018.
- 2018: KEI comments on the NIH license on Anti-Mesothelin CAR to Atara Biotherapeutics, July 13, 2018.
- 2018: KEI and UACT comments on the prospective grant of an exclusive license to Midissia Therapeutics, August 13, 2018.
- 2018: KEI and T1International comments on the prospective grant of an exclusive license to Inversago Pharma, Inc, August 20, 2018.
- 2018: KEI and UACT comments on the prospective grant of exclusive licenses to Sinotau and MTTI, August 28, 2018.
- 2018: NIH Prospective Grant of an Exclusive Patent License to ElevateBio for CAR T cancer treatment, November 4, 2018.
- 2018: Comments on NIH Prospective Exclusive License on Diabetes Treatments, November 20, 2018.
- 2018: Comments on NIH license to Bull Run Capital, Inc. for safer non-lethal antagonist, December 16, 2018.
2019
- 2019: Joint Comments on NIH Prospective License to Sixfold Biosciences on Nanoparticles Technology (and NIH Response), January 7, 2019.
- 2019: Joint Comments on NIH Prospective License to Medigen on RSV and Parainfluenza Vaccines (and NIH Response), January 7, 2019.
- 2019: KEI comments on NIH prospective license to Morphiex on CD47 for solid tumors (and NIH Response), February 20, 2019.
- 2019: Joint comments on NIH prospective license to Ziopharm Oncology on cell therapies for cancer (and NIH Response), February 22, 2019.
- 2019: KEI comments on NIH License to BioE Holdings Inc for polyomaviruses vaccines (and NIH Response), February 22, 2019.
- 2019: Joint NGO comments on Senti Bio License for Development and Commercialization of Next Generation Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like tyrosine kinase 3 (FLT3) Expressing Cancers, April 19, 2019.
- 2019: KEI and UACT comments on NIH license to GLG Pharma over a STAT3 Inhibitor “in all proliferative diseases” (and NIH Response), June 7, 2019.
- 2019: KEI and UACT comment on NIH license to Tailored Therapeutics for the development and commercialization of cell therapies for cancer (and NIH Response), July 2, 2019.
- 2019: KEI and UACT comment on NIH license to Molecular Targeting Technologies, Inc. over Lutetium-177 Radiotherapeutics Against Somatostatin-Receptor Expressing Neuroendocrine Tumors (and NIH Response), July 2, 2019.
- 2019. Joint Comments on NIH Exclusive Licenses for CAR T Technologies to Kite/Gilead (and NIH Response), July 29, 2019.
- 2019: Joint Comments Regarding NIH Proposed Exclusive License to Intima Biosciences for Cancer Therapy (and NIH Response), September 13, 2019.
- 2019: Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma (and NIH Response), September 19, 2019.
- 2019: KEI and UACT Comments to NIH on License in AAV Vectors to Generation Bio and Spark Therapeutics, October 11, 2019.
- 2019: KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology (and NIH response), October 18, 2019.
- 2019: KEI Comments to the NIH on Exclusive License to Opsis Therapeutics for Retinal Cell Therapies, October 18, 2019.
- 2019: KEI and UACT Comments Regarding NIH Exclusive License on GPC3-Expressing Cancer Treatment, November 12, 2019.
2020
- 2020: KEI Comments Regarding NIH Exclusive License on Gene Therapy to Treat Ocular Disease. January 10, 2020.
- 2020: KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy (and NIH Response). February 3, 2020.
- 2020: KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech. April 17, 2020.
- 2020: KEI Comments Regarding NIH Exclusive License for Adoptive Cell Therapy to Lyell Immunopharma. April 17, 2020.
- 2020: KEI Comments on NIH Exclusive License to Kriya Therapeutics for Diabetes and Obesity Treatment. April 30, 2020.
- 2020: KEI and UACT Comments Regarding NIH Exclusive License to Retargeted Therapeutics for Cancer Treatment (and NIH Response). June 8, 2020.
- 2020: Joint Comments on Two NIH Exclusive Licenses to CAR Therapy to Vor Biopharma and Senti Bio. June 15, 2020.
- 2020: Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy (and NIH Response). July 6, 2020.
- 2020: KEI Comments Regarding NIH Exclusive License to Paz Pharmaceuticals for Cancer Treatment. July 7, 2020.
- 2020: KEI Comments Regarding NIH Exclusive License to RNAceuticals for Anti-HIV Antibodies. July 27, 2020.
- 2020: KEI and UACT Comments Regarding NIH Exclusive License to Cytovia for CAR Technology. August 14, 2020.
- 2020: KEI Comments Regarding NIH Exclusive License to PreciThera (and NIH Response). August 20, 2020.
- 2020: KEI and UACT Comments Regarding NIH Exclusive License to ONK Therapeutics (and NIH Response). August 28, 2020.
- 2020: KEI and UACT Comments to NIH on Proposed Exclusive License to Connectyx. September 11, 2020.
- 2020: KEI Comments on Proposed Exclusive License to Connectyx for Degenerative Retinal Disease Treatment. November 6, 2020.
- 2020: KEI Comments on NIH Proposed Exclusive License to St. Louis University. December 3, 2020.
2021
- 2021: KEI Comments on NIH Exclusive License to Morphiex for Cancer Treatment. January 12, 2021.
- 2021: KEI Comments to NIH on Exclusive and Co-Exclusive Licenses to Senti Bio. January 12, 2021.
- 2021: KEI Comments to NIH Proposed Exclusive License to Ziopharm for Cell Therapy Cancer Treatment. February 9, 2021.
- 2021: KEI Comments on NIH Exclusive License to Canadian Firm EpifiZa. February 9, 2021.
- 2021: KEI Comments on NIH Exclusive Licenses to Kyverna on CAR T therapy. March 5, 2021.
- 2021: KEI Comments on NIH Proposed Exclusive License to Iovance for Cancer Cell Therapy. March 12, 2021.
- 2021: KEI Comments on NIH Exclusive License to Ridgeback for FDA-approved Ebola Treatment. March 30, 2021.
- 2021: KEI Comments Regarding NIH Exclusive License to Memorial Sloan Kettering Cancer Center. April 14, 2021.
- 2021: KEI Comments on NIH Exclusive License to Norwegian Firm Zelluna. April 14, 2021.
- 2021: KEI Comments on NIH Exclusive License to Australian firm SubRed. April 26, 2021.
- 2021: KEI Comments to the NIH Regarding Prospective Exclusive License to UK firm Mevox. June 2, 2021.
- 2021: KEI Comments Concerning NIH Exclusive License to Kantum Pharma. June 8, 2021.
- 2021: KEI Comments Regarding NIH Exclusive License to Lyell Immunopharma for Cell Therapy Cancer Treatment. June 8, 2021.
- 2021: KEI Comments on NIH Exclusive License to Panacea for Gene Therapy. July 9, 2021.
- 2021: KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy. July 9, 2021.
- 2021: KEI Comments to the NIH on Exclusive License of AAV Technology to Children’s Medical Research Institute in Australia. July 14, 2021.
- 2021: KEI Comments Regarding NIH Proposed Exclusive License to Yeda. July 27, 2021.
- 2021: KEI Comments to NIH Regarding Proposed Exclusive License to PTC Therapeutics for Gene Therapy. July 27, 2021.
- 2021: KEI Comments Regarding NIH Exclusive License to Progeria Research Foundation for Ultra-Rare Disease Treatment. July 27, 2021.
- 2021: KEI Comments Regarding NIH Prospective License to Blue Water Vaccines for West Nile Vaccine. September 27, 2021.
- 2021: KEI Comments on NIH Prospective Exclusive License to Gilead for HIV Treatment/Cure. October 12, 2021.
- 2021: KEI comments on NIH proposed exclusive license to Neogene Therapeutics CRISPR-Engineered T Cell Therapies for the Treatment of Cancer. November 10, 2021.
2022
- 2022: KEI Comment to the NIH Regarding Exclusive License of Anti-Viral Prevention and Treatment. January 12, 2022.
- 2022: KEI Comments to NIH on Exclusive License to TeraImmune for T-cell Therapy for Multiple Sclerosis. February 9, 2022.
- 2022: KEI Comments Regarding NIH Exclusive License to Syncopation for CAR T Therapy. March 16, 2022.
- 2022: KEI Comments Regarding NIH Prospective Exclusive License to Georgetown University for Pancreatic Cancer Diagnostic. April 28, 2022.
2023
- 2023: KEI Comments Regarding NIH Prospective Exclusive License to Yissum R&D. February 8, 2023.
- 2023: KEI Comments to the NIH on Prospective Exclusive License to BrickBio Treatment for Solid Tumors. March 20, 2023.
- 2023: KEI Comments to NIH Regarding Prospective Exclusive License to Oncala Bio for Cancer Treatment. April 12, 2023.
- 2023: KEI Comments to the NIH Regarding the Prospective Grant of an Exclusive License to Elgia Therapeutics. August 4, 2023.
- 2023: KEI Exchange with the NIH Regarding April 2023 EnZeta Prospective License Notice. April 21, 2023.
- 2023: KEI Comments on NIH License to EnZeta Immunotherapies for Solid Tumors. August 18, 2023.
- 2023: Scarlet TCR: Comments on a NIH prospective exclusive patent license for treatment of HPV cancers. October 6, 2023.
- 2023: KEI Comments Regarding NIH Proposed License T Cell Cancer Therapy to Moonlight Bio. October 12, 2023.
- 2023: KEI and Public Citizen Joint Comments on NIH License to Leyden for Coronavirus Treatment. November 3, 2023.
2024
-
- 2024. KEI Comments to the NIH License on Gene Therapy to Marble Therapeutics. February 22, 2024.
- 2024. KEI Comments to the NIH on Exclusive License to UK Firm Poolbeg Pharma. April 8, 2024.
- 2024. KEI Comments on NIH License to McSAF for Antibody-Drug Conjugates for Cancer. May 28, 2024.
- 2024. KEI Comments on NIH Exclusive License to INTcRON. June 4, 2024.
- 2024. KEI Comments on NIH Exclusive License to Autala for Autoimmune Treatment. September 4, 2024.
- 2024. KEI Comments to NIH on Exclusive License to T-Cure Biosciences for Anti-KK-LC-1 T Cell Receptors Patents. October 28, 2024.
- 2024. KEI Comments on NIH Exclusive License to Columbia for Ebola Technology. December 6, 2024.